Medicines to help smokers quit only fight half the battle

Friday, October 11, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MIAMI, Oct. 10, 2019 /PRNewswire/ -- More than 90 percent of smokers who try to quit fail. The reason may be hiding in their brains.

Many people who try to quit often turn to smoking cessation medications NicoDerm CQ and Chantix. In a study published this week, Florida International University Ph.D. psychology student Jessica

Flannery and a team of scientists found one part of the brain is involved in the formation of tobacco cravings and nicotine withdrawal symptoms, while an entirely separate part of the brain is linked to the severity of the person's actual addiction. Yet, these medications are only targeting one of those.

"This study suggests current medications only treat the symptoms as opposed to the core of the substance-use disease, which is how addicted a person is," said Matthew Sutherland, a cognitive neuroscientist at FIU and senior author of the study. "Instead of a single medication, perhaps multiple medications, each targeting different brain processes, are needed to improve quit rates."

The scientists administered smoking cessation medication to understand changes in brain activity between smokers and nonsmokers. Using functional magnetic resonance imaging (fMRI), the researchers conducted brain scans and found two areas of the brain exhibiting activity as participants performed different parts of a task. The scientists observed brain processes associated with how addicted a person reported being was related to activity in the part of the brain called the striatum. Meanwhile, a smoker's craving for cigarettes was related to activity changes in the brain's habenula.

The World Health Organization estimates there are 1.1 billion cigarette smokers worldwide. More than half are expected to die from smoking-related diseases. According to the U.S. Centers for Disease Control, 68 percent of smokers want to quit and half of those try to do so each year. But the nicotine in tobacco products is highly addictive and only 7 percent actually succeed. This new study linking specific brain processes to nicotine use offers a roadmap for developing new interventions or improving existing ones.

"Progress toward improving withdrawal management and/or relapse prevention is particularly timely as a new generation of nicotine addicted young adults may likely follow the wide-spread adoption of electronic cigarettes and vaping among today's youth," Flannery said.

The research was published in Science Advances and was conducted by psychologists in the Center for Children and Families and Department of Physics in FIU's College of Arts, Sciences & Education as well as a team from the National Institute on Drug Abuse.

The Science Advances article is available at https://advances.sciencemag.org/content/5/10/eaax2084/tab-article-info

Media contact: Rosanna Castro 305-348-5472 roscastr@fiu.edu news.fiu.edu @FIUNews

Cision View original content:http://www.prnewswire.com/news-releases/medicines-to-help-smokers-quit-only-fight-half-the-battle-300936795.html

SOURCE Florida International University



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store